Formosa Pharmaceuticals has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007) in Australia and New Zealand.
APP13007 is a topical eyedrop indicated for the treatment of inflammation and pain following ocular surgery.
Under the agreement, Arrotex receives exclusive commercialization rights in the region. The deal includes upfront payments, regulatory and sales milestones, and royalty considerations.
APP13007 contains clobetasol propionate, a superpotent corticosteroid, and is developed using Formosa’s proprietary APNT nanoparticle formulation platform.
The formulation was approved by the U.S. Food and Drug Administration in 2024 and is designed to:
According to a U.S. survey of 100 ophthalmic surgeons:
The licensed territory sees approximately 250,000 cataract surgeries annually, with anticipated year-on-year growth.
Arrotex, often referred to as “Australia’s Medicines Company,” supplies roughly 50% of the country’s total pharmaceutical volume and has an established footprint in ophthalmology. The company’s national distribution network and pharmacy access are expected to support market uptake.
For Formosa, the partnership extends the geographic reach of APP13007 beyond the United States.
For Arrotex, the agreement strengthens its specialist care portfolio and reinforces its position in ophthalmology.
Executives from both companies highlighted the combination of Formosa’s innovative formulation platform and Arrotex’s commercial infrastructure as key to expanding patient access across Australia and New Zealand.
Formosa Pharmaceuticals is a clinical-stage biotechnology company focused on ophthalmology and oncology. Its APNT nanoparticle technology is designed to enhance dissolution and bioavailability of active pharmaceutical ingredients (APIs) across topical, oral, and inhaled formulations.
Arrotex Pharmaceuticals is Australia’s largest and most diversified pharmaceutical company, offering a broad portfolio of prescription medicines and operating an extensive national distribution network.
The licensing agreement positions APP13007 for commercial rollout in a growing ophthalmic surgery market, while allowing Formosa to leverage a strong local partner to expand access in Australia and New Zealand.